Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

S. Knop, MV. Mateos, MA. Dimopoulos, K. Suzuki, A. Jakubowiak, C. Doyen, P. Lucio, Z. Nagy, G. Usenko, L. Pour, M. Cook, S. Grosicki, A. Crepaldi, AM. Liberati, P. Campbell, T. Shelekhova, SS. Yoon, G. Losava, T. Fujisaki, M. Garg, J. Wang, S....

. 2021 ; 21 (1) : 659. [pub] 20210602

Language English Country Great Britain

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc22004236

BACKGROUND: In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes (PROs) from ALCYONE. METHODS: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaire were administered at baseline, every 3 months (year 1) and every 6 months (until progression). Treatment effects were assessed using a repeated-measures, mixed-effects model. RESULTS: Compliance with PRO assessments was comparable at baseline (> 90%) and throughout study (> 76%) for both treatment groups. Improvements from baseline were observed in both groups for EORTC QLQ-C30 Global Health Status (GHS), most functional scales, symptom scales and EQ-5D-5L visual analog scale (VAS). Between-group differences were significant for GHS (p = 0.0240) and VAS (p = 0.0160) at month 3. Improvements in pain were clinically meaningful in both groups at all assessment time points. Cognitive function declined in both groups, but the magnitude of the decline was not clinically meaningful. CONCLUSIONS: Patients with transplant-ineligible NDMM demonstrated early and continuous improvements in health-related quality of life, including improvements in functioning and symptoms, following treatment with D-VMP or VMP. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02195479 , registered September 21, 2014.

Andrew Love Cancer Centre Geelong Australia

Azienda Ospedaliera Santa Maria Terni Italy

Champalimaud Centre for the Unknown Lisbon Portugal

Clinic of Professional Pathology Saratov Russia

Clinica de Tratamento E Cuiaba Brazil

Clínica Universidad de Navarra Centro de Investigación Médica Aplicada Instituto de Investigación Sanitaria de Navarra Centro de Investigación Biomédica en Red de Cáncer Pamplona Spain

Department of Haematology and Oncology Würzburg University Medical Center Oberdürrbacher Straße 6 97080 Würzburg Germany

Department of Internal Medicine Seoul National University College of Medicine Seoul Republic of Korea

Dnipropetrovsk City Multidisciplinary Clinical Hospital No 4 Dnipropetrovsk Ukraine

Institute of Hematology Department of Experimental Diagnostic and Specialty Medicine University of Bologna Bologna Italy

Janssen Research and Development LLC Spring House PA USA

Janssen Research and Development Raritan NJ USA

Japanese Red Cross Medical Center Tokyo Japan

Leicester Royal Infirmary Leicester UK

LTD Medinvent Institute of Health Tbilisi Georgia

Matsuyama Red Cross Hospital Matsuyama Japan

National and Kapodistrian University of Athens Athens Greece

Semmelweis University Budapest Hungary

Silesian Medical University Katowice Poland

Université Catholique of Louvain CHU UCL Namur Yvoir Belgium

University Hospital Brno Brno Czech Republic

University Hospital of Salamanca Instituto de Investigación Biomédica de Salamanca Salamanca Spain

University Hospitals Birmingham NHS Trust Birmingham UK

University of Chicago Medical Center Chicago IL USA

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004236
003      
CZ-PrNML
005      
20220127145420.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-021-08325-2 $2 doi
035    __
$a (PubMed)34078314
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Knop, Stefan $u Department of Haematology and Oncology, Würzburg University Medical Center, Oberdürrbacher Straße 6, 97080, Würzburg, Germany. knop_s@ukw.de
245    10
$a Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial / $c S. Knop, MV. Mateos, MA. Dimopoulos, K. Suzuki, A. Jakubowiak, C. Doyen, P. Lucio, Z. Nagy, G. Usenko, L. Pour, M. Cook, S. Grosicki, A. Crepaldi, AM. Liberati, P. Campbell, T. Shelekhova, SS. Yoon, G. Losava, T. Fujisaki, M. Garg, J. Wang, S. Wroblewski, A. Kudva, KS. Gries, J. Fastenau, J. San-Miguel, M. Cavo
520    9_
$a BACKGROUND: In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes (PROs) from ALCYONE. METHODS: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaire were administered at baseline, every 3 months (year 1) and every 6 months (until progression). Treatment effects were assessed using a repeated-measures, mixed-effects model. RESULTS: Compliance with PRO assessments was comparable at baseline (> 90%) and throughout study (> 76%) for both treatment groups. Improvements from baseline were observed in both groups for EORTC QLQ-C30 Global Health Status (GHS), most functional scales, symptom scales and EQ-5D-5L visual analog scale (VAS). Between-group differences were significant for GHS (p = 0.0240) and VAS (p = 0.0160) at month 3. Improvements in pain were clinically meaningful in both groups at all assessment time points. Cognitive function declined in both groups, but the magnitude of the decline was not clinically meaningful. CONCLUSIONS: Patients with transplant-ineligible NDMM demonstrated early and continuous improvements in health-related quality of life, including improvements in functioning and symptoms, following treatment with D-VMP or VMP. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02195479 , registered September 21, 2014.
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a bortezomib $x aplikace a dávkování $x škodlivé účinky $7 D000069286
650    _2
$a progrese nemoci $7 D018450
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melfalan $x aplikace a dávkování $x škodlivé účinky $7 D008558
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x komplikace $x diagnóza $x farmakoterapie $x psychologie $7 D009101
650    12
$a hodnocení výsledků péče pacientem $7 D000071066
650    _2
$a prednison $x aplikace a dávkování $x škodlivé účinky $7 D011241
650    12
$a kvalita života $7 D011788
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Mateos, Maria-Victoria $u University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
700    1_
$a Dimopoulos, Meletios A $u National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Suzuki, Kenshi $u Japanese Red Cross Medical Center, Tokyo, Japan
700    1_
$a Jakubowiak, Andrzej $u University of Chicago Medical Center, Chicago, IL, USA
700    1_
$a Doyen, Chantal $u Université Catholique of Louvain, CHU UCL Namur, Yvoir, Belgium
700    1_
$a Lucio, Paulo $u Champalimaud Centre for the Unknown, Lisbon, Portugal
700    1_
$a Nagy, Zsolt $u Semmelweis University, Budapest, Hungary
700    1_
$a Usenko, Ganna $u Dnipropetrovsk City Multidisciplinary Clinical Hospital No. 4, Dnipropetrovsk, Ukraine
700    1_
$a Pour, Ludek $u University Hospital Brno, Brno, Czech Republic
700    1_
$a Cook, Mark $u University Hospitals Birmingham NHS Trust, Birmingham, UK
700    1_
$a Grosicki, Sebastian $u Silesian Medical University, Katowice, Poland
700    1_
$a Crepaldi, Andre $u Clinica de Tratamento E, Cuiaba, Brazil
700    1_
$a Liberati, Anna Marina $u Azienda Ospedaliera "Santa Maria", Terni, Italy
700    1_
$a Campbell, Philip $u Andrew Love Cancer Centre, Geelong, Australia
700    1_
$a Shelekhova, Tatiana $u Clinic of Professional Pathology, Saratov, Russia
700    1_
$a Yoon, Sung-Soo $u Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
700    1_
$a Losava, Genadi $u LTD "Medinvent" Institute of Health, Tbilisi, Georgia
700    1_
$a Fujisaki, Tomoaki $u Matsuyama Red Cross Hospital, Matsuyama, Japan
700    1_
$a Garg, Mamta $u Leicester Royal Infirmary, Leicester, UK
700    1_
$a Wang, Jianping $u Janssen Research and Development, Raritan, NJ, USA
700    1_
$a Wroblewski, Susan $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Kudva, Anupa $u Janssen Research and Development, Raritan, NJ, USA
700    1_
$a Gries, Katharine S $u Janssen Research and Development, Raritan, NJ, USA
700    1_
$a Fastenau, John $u Janssen Research and Development, Raritan, NJ, USA
700    1_
$a San-Miguel, Jesus $u Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain
700    1_
$a Cavo, Michele $u Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 21, č. 1 (2021), s. 659
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34078314 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145417 $b ABA008
999    __
$a ok $b bmc $g 1751635 $s 1155385
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 21 $c 1 $d 659 $e 20210602 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options